Modera erate tely Mod High to e H w at ig o er h L d o M V e r y w H Tata Pharma & Healthcare Fund o i L g (An open ended equity scheme investing in Pharma and Healthcare Services Sector) h Riskometer Investors understand that their principal As on 31st July 2021 PORTFOLIO will be at Very High Risk

INVESTMENT STYLE Company name No. of Market Value % of Company name No. of Market Value % of Primarily focuses on investment in at least 80% of its net Shares Rs. Lakhs Assets Shares Rs. Lakhs Assets assets in equity/equity related instruments of the companies in the Pharma & Healthcare sectors in India. Equity & Equity Related Total 58001.80 97.46 Ltd. 167000 1014.44 1.70 INVESTMENT OBJECTIVE Healthcare Services Abbott India Ltd. 5100 969.65 1.63 The investment objective of the scheme is to seek long Enterprise Ltd. 78000 3147.30 5.29 Glaxosmithkline Pharmaceuticals Ltd. 53363 857.94 1.44 term capital appreciation by investing atleast 80% of its Ltd. 795000 1993.07 3.35 Gland Pharma Ltd. 19662 772.81 1.30 net assets in equity/equity related instruments of the companies in the pharma & healthcare sectors in Narayana Hrudayalaya Ltd. 301420 1476.51 2.48 India.However, there is no assurance or guarantee that the investment objective of the Scheme will be Krishna Institute Of Medical Sciences Ltd. 116982 1410.16 2.37 Other Equities^ 1728.81 2.90 achieved.The Scheme does not assure or guarantee any Syngene International Ltd. 200000 1277.60 2.15 returns. Repo 1857.80 3.12 Metropolis Healthcare Ltd. 43000 1223.24 2.06 DATE OF ALLOTMENT Portfolio Total 59859.60 100.58 Healthcare Global Enterprises Ltd. 410000 1025.82 1.72 December 28, 2015 Net Current Liabilities -346.12 -0.58 Pharmaceuticals FUND MANAGER Sun Pharmaceutical Industries Ltd. 790100 6114.98 10.27 Net Assets 59513.48 100.00 Meeta Shetty (Managing Since 09-Mar-21 and overall experience of 15 years) Divi Laboratories Ltd. 104500 5126.87 8.61 ^ Exposure less than 1% has been clubbed under Other Equities Ltd. 500000 4600.25 7.73 BENCHMARK Dr Reddys Laboratories Ltd. 96000 4522.75 7.60 Nifty Pharma TRI Ltd. 490000 4491.34 7.55 NAV Ltd. 111365 3846.10 6.46 Direct - IDCW : 19.4324 Ltd. 133726 2814.13 4.73 Direct - Growth : 19.4324 Regular - IDCW : 17.7284 J.B.Chemicals & Pharmaceuticals Ltd. 103000 1867.65 3.14 Regular - Growth : 17.7284 Fdc Ltd. 378183 1407.60 2.37 FUND SIZE Procter & Gamble Health Ltd. 26000 1392.92 2.34 Rs. 595.13 (Rs. in Cr.) Lupin Ltd. 123000 1362.10 2.29 MONTHLY AVERAGE AUM Indoco Remedies Ltd. 279000 1254.66 2.11 Rs. 586.72 (Rs. in Cr.) Ltd. 53087 1216.81 2.04 TURN OVER India Ltd. 13000 1086.29 1.83 Portfolio Turnover (Total) 41.31% Portfolio Turnover (Equity component only) 41.31%

EXPENSE RATIO** Direct 1.06 SIP - If you had invested INR 10000 every month Regular 2.57 **Note: The rates specified are actual month end expenses charged 1 Year 3 Year 5 Year 7 Year 10 Year Since Inception as on Jul 31, 2021. The above ratio includes the Service tax on Investment Management Fees. The above ratio excludes, borrowing cost, wherever applicable. Total Amount Invested (Rs.) 120,000 360,000 600,000 NA NA 670,000 VOLATILITY MEASURES^ FUND BENCHMARK Total Value as on Jul 31, 2021 (Rs.) 146,752 608,250 1,089,798 NA NA 1,218,738 Std. Dev (Annualised) 19.09 25.40 Returns 44.21% 37.32% 24.14% NA NA 21.45% Sharpe Ratio 0.33 0.18 Total Value of B: Nifty Pharma TRI 140,773 547,138 910,963 NA NA 1,003,151 Portfolio Beta 0.70 1.00 R Squared 0.87 1.00 B: Nifty Pharma TRI 33.92% 29.25% 16.75% NA NA 14.39% Treynor 2.59 1.28 Total Value of AB: Nifty 50 TRI 143,247 497,089 914,029 NA NA 1,065,565 Jenson 0.92 NA 16.57% ^Risk-free rate based on the FBIL Overnight MIBOR rate of 3.40% as AB: Nifty 50 TRI 38.15% 22.18% 16.88% NA NA on Jul 30, 2021 (Inception date :28-Dec-2015) (First Installment date : 01-Jan-2016) For calculation methodology please refer to Pg 68 Past performance may or may not be sustained in the future. Returns greater than 1 year period are compounded annualized. Income Distribution cum capital MINIMUM INVESTMENT / withdrawals are assumed to be reinvested and bonus is adjusted. Load is not taken in to consideration. For SIP returns, monthly investment of equal amounts invested MULTIPLES FOR NEW INVESTMENT on the 1st day of every month has been considered. Rs. 5,000/- and in multiples of Re. 1/- thereafter. For scheme performance refer pages 53 - 68. *B: Benchmark, AB: Additional Benchmark ADDITIONAL INVESTMENT/ Source: MFI Explorer MULTIPLES FOR EXISTING INVESTORS Rs. 1,000/- and in multiples of Re. 1/- thereafter. Top 10 Holdings Equity Sector Allocation LOAD STRUCTURE Issuer Name % to NAV Entry Load : Not Applicable Sun Pharmaceutical Industries Ltd. 10.27 Exit Load : 0.25% of NAV if redeemed/switched out before 30 Divi Laboratories Ltd. 8.61 Pharma 77.28% days from the date of allotment. Cipla Ltd. 7.73 Please refer to our Tata Mutual Fund website for Dr. Reddys Labaratories Ltd. 7.60 fundamental changes, wherever applicable Aurobindo Pharma Ltd. 7.55 Alkem Laboratories Ltd. 6.46 Apollo Hospitals Enterprise Ltd. 5.29 Healthcare Services Ipca Labs 4.73 20.18% Fortis Healthcare Ltd. 3.35 J.b.chemicals & Pharmaceuticals Ltd. 3.14 Total 64.73 0.00% 16.00% 32.00% 48.00% 64.00% 80.00% 96.00%

Market Capitalisation wise Exposure NAV Movement

Large Cap 52.42% Tata India Pharma And Healthcare Fund - Reg - Growth Nifty Pharma TRI 210 Mid Cap 28.38% 182 154 Small Cap 19.20% 126 98

Market Capitalisation is as per list provided by AMFI. 70 Jul-18 Jul-19 Jul-20 Jul-21 www.tatamutualfund.com Mutual Fund investments are subject to market risks, read all scheme related documents carefully TATA MUTUAL FUND 25